Abstracts - faqs.org

Abstracts

News, opinion and commentary

Search abstracts:
Abstracts » News, opinion and commentary

Investors hoping to get rich from Tribune spinoff may be let down

Article Abstract:

The outlook of investors on 42% projected rise in stocks of Tribune Co.'s, following company's plans to revamp television stations, is presented.

Author: Ellison, Sarah, Karnitschnig, Matthew
Publisher: Bell Globemedia Interactive
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2006
Television Broadcasting, Financial management, Organizational history, Newspapers, Television broadcasting stations, TV Stations, Newspaper publishing, Company restructuring/company reorganization, Reorganization and restructuring, Investor relations, TRB, Television stations, Company organization, Tribune Co. (Chicago, Illinois)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Will investors keep swallowing Apple hype?

Article Abstract:

The forecasts of the stock values of Apple Computers are discussed.

Author: Vox, Derek Decloet
Publisher: Bell Globemedia Interactive
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2005
Electronic computers, Computer industry, Microcomputer industry, AAPL, Apple Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: United States, Securities, Company securities, Company business forecast/projection, Company forecasts
Similar abstracts:
  • Abstracts: GM debt issue revs Street talk. Global shares sink on bid news. DBRS downgrades Ipsco securities
  • Abstracts: McKesson falls $9B on accounting problem. Anheuser-Busch profit rises with prices. Talbots profit falls on summer discounts
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.